CORRESP Filing
Biodexa Pharmaceuticals Plc
Date: Sept. 29, 2025 · CIK: 0001643918 · Accession: 0001214659-25-014284
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-290554
Letter
Biodexa Pharmaceuticals PLC
1 Caspian Point
Caspian Way
Cardiff, CF10 4DQ
United Kingdom
September 29, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E. Washington, D.C. 20549
Attention: Jessica Dickerson
Re: Biodexa Pharmaceuticals PLC Registration Statement on Form F-3 File No. 333-290554 (the "Registration Statement") Acceleration Request
Ladies and Gentlemen:
In accordance with Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, Biodexa Pharmaceuticals PLC (the "Registrant") hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to Tuesday, September 30, 2025, at 4:00 p.m., Eastern Time, or as soon as thereafter practicable.
The cooperation of the staff in meeting the timetable described above is very much appreciated.
Please contact Jason S. McCaffrey of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (617) 348-4416 with any questions regarding this request.
Very truly yours,
Biodexa Pharmaceuticals PLC
Show Raw Text
CORRESP 1 filename1.htm Biodexa Pharmaceuticals PLC 1 Caspian Point Caspian Way Cardiff, CF10 4DQ United Kingdom September 29, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Jessica Dickerson Re: Biodexa Pharmaceuticals PLC Registration Statement on Form F-3 File No. 333-290554 (the "Registration Statement") Acceleration Request Ladies and Gentlemen: In accordance with Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, Biodexa Pharmaceuticals PLC (the "Registrant") hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to Tuesday, September 30, 2025, at 4:00 p.m., Eastern Time, or as soon as thereafter practicable. The cooperation of the staff in meeting the timetable described above is very much appreciated. Please contact Jason S. McCaffrey of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (617) 348-4416 with any questions regarding this request. Very truly yours, Biodexa Pharmaceuticals PLC /s/ Stephen Stamp Stephen Stamp Chief Executive Officer cc: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. Jason S. McCaffrey, Esq.